---
title: "Stocks in Play: Oncolytics Biotech Inc"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284230718.md"
description: "Oncolytics Biotech Inc announced a successful Type C meeting with the U.S. FDA regarding the pivotal clinical study design for pelareorep, aimed at treating unresectable metastatic squamous cell carcinoma of the anal canal. CEO Jared Kelly expressed gratitude for the FDA's guidance in establishing an efficient approval pathway. The company's shares are currently trading up $0.02 at $1.05."
datetime: "2026-04-27T13:57:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284230718.md)
  - [en](https://longbridge.com/en/news/284230718.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284230718.md)
---

# Stocks in Play: Oncolytics Biotech Inc

**09:50 AM EST - Oncolytics Biotech Inc :** Announces that a Type C meeting with the U.S. Food and Drug Administration has resulted in alignment on the design of a pivotal clinical study to support approval of pelareorep in patients with unresectable metastatic squamous cell carcinoma of the anal canal. “We want to thank the FDA for its very clear guidance and helping us create an efficient pathway for pelareorep in a disease that is desperate for new treatments,” said Jared Kelly, Chief Executive Officer of Oncolytics. Oncolytics Biotech Inc shares N.ONCY are trading **up $0.02** at $1.05.  

_Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=6965975253781036_

### Related Stocks

- [ONCY.US](https://longbridge.com/en/quote/ONCY.US.md)

## Related News & Research

- [Oncolytics Reports 19.5-Month Median Duration of Response in 2L KRAS-Mutant MSS mCRC](https://longbridge.com/en/news/285078415.md)
- [Oncolytics Biotech Completes Domestication to Nevada with New Governance](https://longbridge.com/en/news/281401031.md)
- [Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares](https://longbridge.com/en/news/286950631.md)
- [A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data](https://longbridge.com/en/news/286722721.md)
- [Oncolytics to Present Pelareorep Translational Data at AACR 2026 Showing Immune Activation in Pancreatic and Breast Cancer](https://longbridge.com/en/news/279797186.md)